Switch to:
More From Other Websites
3 Under-the-Radar Risks for Gilead Sciences Mar 27 2015
Gilead CEO scores $187 million in 2014 gains Mar 27 2015
Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog Mar 27 2015
Portfolio winner's top picks at Engage Mar 27 2015
Gilead Sciences: Big in Japan? Mar 26 2015
The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press Releases Mar 26 2015
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the... Mar 26 2015
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the... Mar 26 2015
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the... Mar 26 2015
Read This Before You Sell Gilead Sciences Mar 25 2015
Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst... Mar 25 2015
The 10 overseas shares most popular with British investors Mar 25 2015
Why Deutsche Bank Says to Buy Gilead and Vertex Pullbacks Mar 25 2015
Insight - Top U.S. CEOs reaped billions from stock gains in recent years, Reuters analysis shows Mar 25 2015
Why Teva Pharmaceuticals Could Gain 25% Mar 24 2015
Company News for March 24, 2015 - Corporate Summary Mar 24 2015
High Alert for Signs of Biotech Collapse Makes for Nervous Investors Mar 24 2015
Can this fund deliver 300pc again over the next five years? Mar 24 2015
Could Gilead's Dividend Have Additional Upside? Mar 23 2015
Gilead Sciences (GILD) Stock Declined Today on Hepatitis C Treatment Warning Mar 23 2015


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK